We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.78%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.01B
AUM Growth
+$119M
Cap. Flow
-$210M
Cap. Flow %
-2.99%
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$40.7M
2
LLY icon
Eli Lilly
LLY
+$35.4M
3
MRK icon
Merck
MRK
+$34M
4
HUM icon
Humana
HUM
+$29.6M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$29.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$57.6M
2
APLS
Apellis Pharmaceuticals
APLS
+$51M
3
BSX icon
Boston Scientific
BSX
+$40.6M
4
HCA icon
HCA Healthcare
HCA
+$39.8M
5
ISRG icon
Intuitive Surgical
ISRG
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Industrials 0.87%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDX icon
26
Becton Dickinson
BDX
$43.6B
$89.2M 1.27%
337,723
-10,320
-3% -$2.62M
PEN icon
27
Penumbra
PEN
$12.5B
$80.6M 1.15%
234,220
-3,952
-2% -$1.21M
SWAV
28
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$77.2M 1.1%
270,526
-10,850
-4% -$3.01M
OPCH icon
29
Option Care Health
OPCH
$3.41B
$74.3M 1.06%
2,287,623
-154,562
-6% -$4.66M
INSM icon
30
Insmed
INSM
$23.5B
$69.6M 0.99%
3,300,911
+7,809
+0.2% +$148K
OM icon
31
Outset Medical
OM
$77.9M
$68.4M 0.98%
208,392
+14,608
+8% +$4.46M
CRL icon
32
Charles River Laboratories
CRL
$10.8B
$66.1M 0.94%
314,513
+12,067
+4% +$2.4M
CLDX icon
33
Celldex Therapeutics
CLDX
$2.77B
$61.1M 0.87%
1,800,000
– –
ACCD
34
DELISTED
Accolade Inc
ACCD
$60.9M 0.87%
4,521,059
+479,258
+12% +$6.22M
ALGN icon
35
Align Technology
ALGN
$12.7B
$60.5M 0.86%
171,140
– –
IDXX icon
36
Idexx Laboratories
IDXX
$44.8B
$57.5M 0.82%
114,441
+3,513
+3% +$1.68M
HUM icon
37
Humana
HUM
$48B
$57M 0.81%
127,373
+58,803
+86% +$29.6M
VEEV icon
38
Veeva Systems
VEEV
$31.7B
$53.6M 0.76%
271,046
+8,061
+3% +$1.47M
ARVN icon
39
Arvinas
ARVN
$517M
$52.8M 0.75%
2,127,000
– –
RLAY icon
40
Relay Therapeutics
RLAY
$4.34B
$52.4M 0.75%
4,170,800
-1,800
-0% -$22.4K
TMDX icon
41
Transmedics
TMDX
$2.56B
$51.4M 0.73%
612,613
-16,871
-3% -$1.29M
MGNX icon
42
MacroGenics
MGNX
$285M
$51.4M 0.73%
9,609,913
– –
TNDM icon
43
Tandem Diabetes Care
TNDM
$1.17B
$51.4M 0.73%
2,092,934
+299,171
+17% +$9.62M
BIO icon
44
Bio-Rad Laboratories Class A
BIO
$8.15B
$51M 0.73%
134,533
+20,794
+18% +$8.46M
CRSP icon
45
CRISPR Therapeutics
CRSP
$4.71B
$50.5M 0.72%
899,300
-500
-0.1% -$28.4K
TMO icon
46
Thermo Fisher Scientific
TMO
$198B
$50.1M 0.72%
96,101
+9,768
+11% +$5.27M
MOH icon
47
Molina Healthcare
MOH
$11.7B
$49.5M 0.71%
164,338
+21,729
+15% +$6.25M
HCA icon
48
HCA Healthcare
HCA
$82.3B
$48.7M 0.69%
160,515
-143,271
-47% -$39.8M
EXEL icon
49
Exelixis
EXEL
$14.1B
$48.4M 0.69%
2,534,000
-75,000
-3% -$1.45M
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
$47.2M 0.67%
518,495
-590,887
-53% -$51M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2023 Portfolio in Review

As of Q2 2023, Bellevue Group held 168 positions worth $7.01B, up 1.7% from $6.89B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group's Q2 2023 filing shows 9 new, 52 increased, 52 reduced and 12 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M. The largest sale was Sarepta Therapeutics, an estimated $57.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2023 buy was POINT Biopharma Global Inc. Common Stock: 1,256,197 shares worth $11.4M.
  • Bellevue Group added most to Evolent Health in Q2 2023, an estimated $40.7M increase.
  • Bellevue Group's biggest Q2 2023 reduction was Sarepta Therapeutics, cutting an estimated $57.6M.
  • Bellevue Group fully exited Pfizer in Q2 2023, selling an estimated $30.2M.
  • Bellevue Group's ten largest holdings make up 37% of its $7.01B portfolio in Q2 2023.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2023.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $7.01B.

Based on Bellevue Group's 13F filing for Q2 2023, filed 14 Aug 2023.